Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
2.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
3.

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P.

Oncoimmunology. 2018 Apr 18;7(8):e1450715. doi: 10.1080/2162402X.2018.1450715. eCollection 2018.

4.

Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

Idorn M, Thor Straten P.

Cells. 2018 Aug 17;7(8). pii: E108. doi: 10.3390/cells7080108. Review.

5.

Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.

Mathiesen CBK, Carlsson MC, Brand S, Möller SR, Idorn M, Thor Straten P, Pedersen AE, Dabelsteen S, Halim A, Würtzen PA, Brimnes J, Ipsen H, Petersen BL, Wandall HH.

J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17. No abstract available.

PMID:
30125661
6.

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.

Idorn M, Olsen M, Halldórsdóttir HR, Skadborg SK, Pedersen M, Høgdall C, Høgdall E, Met Ö, Thor Straten P.

Oncoimmunology. 2017 Dec 26;7(4):e1412029. doi: 10.1080/2162402X.2017.1412029. eCollection 2018.

7.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

8.

Exercise and cancer: from "healthy" to "therapeutic"?

Idorn M, Thor Straten P.

Cancer Immunol Immunother. 2017 May;66(5):667-671. doi: 10.1007/s00262-017-1985-z. Epub 2017 Mar 21. Review.

9.

Exercise: A new role for an old tool.

Idorn M, Thor Straten P.

Mol Cell Oncol. 2016 Apr 15;3(4):e1163005. doi: 10.1080/23723556.2016.1163005. eCollection 2016 Jul.

10.

Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.

Ekström K, Dalsgaard M, Iversen K, Pedersen-Bjergaard U, Vejlstrup N, Diemar SS, Idorn M, Thorsteinsson B, Engstrøm T.

Scand Cardiovasc J. 2017 Feb;51(1):8-14. doi: 10.1080/14017431.2016.1197417. Epub 2016 Jul 5.

PMID:
27309633
11.

Exercise-Dependent Regulation of NK Cells in Cancer Protection.

Idorn M, Hojman P.

Trends Mol Med. 2016 Jul;22(7):565-577. doi: 10.1016/j.molmed.2016.05.007. Epub 2016 Jun 1. Review.

PMID:
27262760
12.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

Idorn M, Thor Straten P, Svane IM, Met Ö.

Methods Mol Biol. 2016;1428:261-76. doi: 10.1007/978-1-4939-3625-0_17.

PMID:
27236805
13.

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, Thor Straten P, Hojman P.

Cell Metab. 2016 Mar 8;23(3):554-62. doi: 10.1016/j.cmet.2016.01.011. Epub 2016 Feb 16.

14.

Influence of acute glycaemic level on measures of myocardial infarction in non-diabetic pigs.

Diemar SS, Sejling AS, Iversen KK, Engstrøm T, Honge JL, Tønder N, Vejlstrup N, Idorn M, Ekström K, Pedersen-Bjergaard U, Thorsteinsson B, Dalsgaard M.

Scand Cardiovasc J. 2015;49(6):376-82. doi: 10.3109/14017431.2015.1085079. Epub 2015 Sep 10.

PMID:
26359322
15.

Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.

Køllgaard T, Ugurel-Becker S, Idorn M, Andersen MH, Becker JC, Straten PT.

PLoS One. 2015 Jul 15;10(7):e0131934. doi: 10.1371/journal.pone.0131934. eCollection 2015.

16.

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

Idorn M, Køllgaard T, Kongsted P, Sengeløv L, Thor Straten P.

Cancer Immunol Immunother. 2014 Nov;63(11):1177-87. doi: 10.1007/s00262-014-1591-2. Epub 2014 Aug 2.

PMID:
25085000
17.

Spontaneous presence of FOXO3-specific T cells in cancer patients.

Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH.

Oncoimmunology. 2014 Nov 14;3(8):e953411. eCollection 2014.

18.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

Sittig SP, Køllgaard T, Grønbæk K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P.

Oncoimmunology. 2013 Sep 1;2(9):e26014. Epub 2013 Sep 26.

19.

High frequency of T cells specific for cryptic epitopes in melanoma patients.

Andersen RS, Andersen SR, Hjortsø MD, Lyngaa R, Idorn M, Køllgård TM, Met O, Thor Straten P, Hadrup SR.

Oncoimmunology. 2013 Jul 1;2(7):e25374.

20.

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses.

Køllgaard T, Klausen TW, Idorn M, Holmgaard RB, Straten PT, Andersen MH.

Oncoimmunology. 2012 Jul 1;1(4):441-447.

Supplemental Content

Loading ...
Support Center